Cargando…

Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program

BACKGROUND: Globalization of clinical trials has important consequences for trial planning and interpretation. This study investigated heterogeneity in patient characteristics and outcomes among world regions in the global idalopirdine Phase 3 clinical program. METHODS: Data were pooled from three 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, Jeffrey L., Atri, Alireza, Ballard, Clive, Boneva, Neli, Frölich, Lutz, Molinuevo, José Luis, Raket, Lars Lau, Tariot, Pierre N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260857/ https://www.ncbi.nlm.nih.gov/pubmed/30474567 http://dx.doi.org/10.1186/s13195-018-0443-2

Ejemplares similares

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Statistical Disease Progression Modeling in Alzheimer Disease
por: Raket, Lars Lau
Publicado: (2020)

Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders
por: El-Hayek, Youssef H., et al.
Publicado: (2019)

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials
por: Grill, Joshua D, et al.
Publicado: (2015)

Longitudinal changes in hippocampal texture from healthy aging to Alzheimer’s disease
por: Wearn, Alfie, et al.
Publicado: (2023)

Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
por: Cummings, Jeffrey L., et al.
Publicado: (2019)

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
por: Atri, Alireza, et al.
Publicado: (2013)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Personalising Alzheimer’s Disease progression using brain atrophy markers
por: Verdi, Serena, et al.
Publicado: (2023)

Disease Progression in Multiple System Atrophy—Novel Modeling Framework and Predictive Factors
por: Kühnel, Line, et al.
Publicado: (2022)

Globalization of Alzheimer's disease clinical trials
por: Cummings, Jeffrey, et al.
Publicado: (2011)

Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease
por: Lawn, Timothy, et al.
Publicado: (2021)

Drug development in Alzheimer’s disease: the path to 2025
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Present Algorithms and Future Treatments for Alzheimer’s Disease
por: Grossberg, George T., et al.
Publicado: (2019)

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
por: Assunção, Sheila Seleri, et al.
Publicado: (2022)

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
por: Corbett, Anne, et al.
Publicado: (2013)

FLAME: A computerized neuropsychological composite for trials in early dementia
por: Brooker, Helen, et al.
Publicado: (2020)

Multinational enterprises and the global economy /
por: Dunning, John H.
Publicado: (1993)

Severe agitation in severe early-onset Alzheimer’s disease resolves with ECT
por: Aksay, Suna Su, et al.
Publicado: (2014)

On the path to 2025: understanding the Alzheimer’s disease continuum
por: Aisen, Paul S., et al.
Publicado: (2017)

Psychosis in Alzheimer’s Disease
por: Ballard, Clive, et al.
Publicado: (2020)

Geographic variation in Alzheimer’s disease mortality
por: Topping, Michael, et al.
Publicado: (2021)

Development and assessment of a brief screening tool for psychosis in dementia
por: Cummings, Jeffrey L., et al.
Publicado: (2021)

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
por: Caprioglio, Camilla, et al.
Publicado: (2022)

Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit
por: Frölich, Lutz, et al.
Publicado: (2021)

Alzheimer’s disease progression by geographical region in a clinical trial setting
por: Henley, David B, et al.
Publicado: (2015)

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
por: Molinuevo, José L, et al.
Publicado: (2015)

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
por: Lanctôt, Krista L., et al.
Publicado: (2017)

Case report: a giant arachnoid cyst masking Alzheimer’s disease
por: Wahl, Anna-Sophia, et al.
Publicado: (2019)

Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report
por: Gauthier, Serge, et al.
Publicado: (2020)

Geographical diversification using ETFs: Multinational evidence from COVID-19 pandemic
por: Yousefi, Hamed, et al.
Publicado: (2022)

Rising Geographic Variation in Alzheimer's Disease Mortality
por: Ho, Jessica, et al.
Publicado: (2021)

Rising Geographic Variation in Alzheimer's Disease Mortality
por: Franco, Yujin, et al.
Publicado: (2021)

Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
por: Bernstein, Olivia M., et al.
Publicado: (2021)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012)

Reduced thermal sensitivity and increased opioidergic tone in the TASTPM mouse model of Alzheimer's disease
por: Aman, Yahyah, et al.
Publicado: (2016)

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
por: Atri, Alireza, et al.
Publicado: (2015)

Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease
por: Raket, Lars Lau, et al.
Publicado: (2022)

Real-World Use of Symptomatic Treatments in Early Alzheimer’s Disease
por: Garcia, Maria João, et al.
Publicado: (2023)

Editorial: Digital brain health
por: Raket, Lars Lau, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oapk35r6bgrfh5gd286lmrne05